Aurora Seeks ASC Order Against Curaleaf's Hostile Bid Circular
ACB sits 64% above its 52-week low of $2.56.
Summary
Aurora filed an application with the Alberta Securities Commission seeking an order requiring Curaleaf to correct deficiencies in its hostile bid circular, including missing pro forma financials and a shortened deposit period that Aurora says triggers its Shareholder Rights Plan.
Key Events · Legal and Risk Events · ACB
-
ASC Application Filed
Aurora filed an application with the Alberta Securities Commission on September 23, 2026, seeking an order requiring Curaleaf to comply with securities laws in connection with its hostile bid.
-
Three Deficiencies Alleged
Aurora alleges Curaleaf's circular fails to provide pro forma financial statements, fails to hold the bid open for the minimum 105-day deposit period, and fails to publish a French-language notice in Québec.
-
Rights Plan Trigger
Aurora states Curaleaf's failure to comply with the 105-day deposit period means the hostile bid does not qualify as a 'permitted bid' under Aurora's Shareholder Rights Plan, which would be triggered if Curaleaf acquires more than 20% of Aurora's shares.
-
Board Reaffirms Rejection
Aurora's Board unanimously recommends shareholders reject the hostile bid by taking no action and not tendering shares, and urges those who have tendered to withdraw.
Analysis · ACB · Life Sciences
Aurora has escalated its defense against Curaleaf's hostile takeover bid by filing a formal application with the Alberta Securities Commission. The company alleges Curaleaf's bid circular fails to provide pro forma financial statements, does not hold the bid open for the required 105-day deposit period, and omits a French-language notice in Québec. Critically, Aurora argues the 105-day deficiency means Curaleaf's bid does not qualify as a 'permitted bid' under Aurora's Shareholder Rights Plan, which would trigger the Rights Plan if Curaleaf acquires more than 20% of Aurora's shares. This is a material legal escalation that could delay or derail the hostile bid and directly affects shareholder decision-making.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACB was trading at $4.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $273.6M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.